Relmada Therapeutics, Inc. (RLMD), a clinical-stage biotechnology company, on Thursday announced the acquisition of Sepranolone, a Phase 2b-ready neurosteroid, from Asarina Pharma AB.
Sepranolone, a first-in-class GABAA Modulating Steroid Antagonist or GAMSA, is being developed for the treatment of Tourette syndrome or TS and other compulsive disorders.
Sepranolone selectively targets the GABAA pathway to counteract the effects of Allopregnanolone, a neurosteroid implicated in TS. Phase 2a clinical results showed a 28 percent reduction in tic severity and significant improvements in quality of life, with no CNS off-target effects.
This acquisition aligns with Relmada's strategy to expand its CNS portfolio and provides a promising first-line treatment option for TS, a condition with unmet treatment needs.
Relmada plans to advance Sepranolone through further clinical development, with an investor update on next steps expected later in 2025.
Currently, RLMD is trading at $0.401 up by 5.66%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.